	US 12,239,646 B2
	Cancer diagnostic and treatment
Matthew Meyerson, Boston, MA (US); and Susan Bullman, Boston, MA (US)
Assigned to DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US)
Appl. No. 16/632,368
Filed by DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US)
PCT Filed Jul. 19, 2018, PCT No. PCT/US2018/042966 § 371(c)(1), (2) Date Jan. 19, 2020, PCT Pub. No. WO2019/018694, PCT Pub. Date Jan. 24, 2019.
Claims priority of provisional application 62/534,672, filed on Jul. 19, 2017.
Prior Publication US 2020/0405720 A1, Dec. 31, 2020
Int. Cl. A61K 31/513 (2006.01); A61K 31/4164 (2006.01); A61K 45/06 (2006.01); C12Q 1/04 (2006.01); C12Q 1/689 (2018.01)

CPC A61K 31/513 (2013.01) [A61K 31/4164 (2013.01); A61K 45/06 (2013.01); C12Q 1/04 (2013.01); C12Q 1/689 (2013.01)]

24 Claims

1. A method of treating or preventing infection in a subject having a detectable colorectal Fusobacterium infection comprising:

administering systemically 5-fluorouracil or an analogue thereof, or a prodrug of 5-flurouracil or analogue thereof to the subject.